Trip.com Groupの空売り状況は、投資家がTrip.com Groupの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Trip.com Group (NASDAQ:TCOM) 株価情報, 空売り情報

Trip.com Group

Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Before the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from its online platform, but the company also maintains offline call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Tongcheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.

Trip.com Group Limited - American Depositary Shares

Trip.com Group Ltd

TRIP COM GROUP ADR REP ORD

WIIM

Teradata shares are trading lower after the company reported Q3 financial results and issued Q4 adjusted EPS guidance below estimates.

PINC

Premier shares are trading higher after the company reported better-than-expected Q1 financial results.

Microsoft Corp.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) November Xbox Game Pass lineup offers a diverse selection, featuring everything from tactical RPGs to quirky simulators and <a href="https://www.benzinga.com/general/gaming">high-fidelity flight experiences.</a>
Here's what's coming to Game Pass this month, as <a href="https://news.xbox.com/en-us/2024/11/04/xbox-game-pass-november-2024-wave-1/">announced</a> in an Xbox Wire post:
<ul>
<li>Metal Slug Tactics (Cloud, Console, and PC – Nov. 5) Dive into this dynamic tactical RPG that combines the iconic run-and-gun action of the Metal Slug series with roguelite elements. Assemble your squad and conquer the battlefield in this strategic twist on a classic.</li>
</ul>
See Also: <a href="https://www.benzinga.com/general/gaming/24/11/41694104/microsofts-decision-to-shut-down-arkane-austin-called-stupid-by-studio-founder">Microsoft&#8217;s Decision To Shut Down Arkane Austin Called &#8216;Stupid&#8217; By Studio Founder</a>
<ul>
<li>StarCraft: Remastered (PC – Nov. 5) Experience the legendary sci-fi real-time strategy game that set the bar for the genre. With enhanced graphics, relive the battles between the Terran, Protoss, and Zerg in this definitive version of the original StarCraft.</li>
<li>StarCraft II: Campaign Collection (PC – Nov. 5) Delve into the epic campaigns of StarCraft II, featuring immersive single-player stories and intense strategy gameplay. This collection brings together the entire StarCraft II narrative, perfect for fans and newcomers alike.</li>
<li>Go Mecha Ball (Console – Nov. 6) Engage in fast-paced, mecha-themed action as you control a ball-shaped robot on a mission. This title combines unique mechanics and challenging levels, offering a fresh take on robot combat.</li>
<li>Harold Halibut (Xbox Series X&#x7C;S – Nov. 6) Step into an underwater world crafted with stop-motion aesthetics in this narrative-driven adventure. Follow Harold, a lab assistant on a spaceship submerged in an ocean, as he unravels a heartfelt story.</li>
<li>The Rewinder (Console – Nov. 6) Inspired by Chinese folklore, this puzzle-adventure game follows the journey of a Rewinder who can manipulate memories. Help lost souls resolve their regrets in a mystical, hand-drawn world.</li>
<li>Turnip Boy Robs a Bank (Console – Nov. 6) Take control of the mischievous Turnip Boy in this quirky action-adventure, where he teams up with a mob of veggies to rob a bank. Expect humor, action, and plenty of surprises.</li>
<li>Goat Simulator Remastered (Cloud, PC, and Xbox Series X&#x7C;S – Nov. 7) The ultimate chaos simulator returns with upgraded graphics and classic DLCs. Headbutt, flip, and lick your way through a sandbox world in this redefined edition of the fan-favorite Goat Simulator.</li>
<li>Microsoft Flight Simulator 2024 (Cloud, PC, and Xbox Series X&#x7C;S – Nov. 19) Push your piloting skills to new heights in the latest installment of Microsoft Flight Simulator. Featuring a vast fleet of aircraft and the most realistic world map to date, this edition brings dynamically generated missions and the ultimate in simulation realism.</li>
</ul>
<h3 class="wp-block-heading">Games Leaving Game Pass On Nov. 15, 2024:</h3>
Be sure to wrap up your gameplay in the following titles before they leave the service:
<ul>
<li>Dicey Dungeons (Cloud, Console, and PC)</li>
<li>Dungeons 4 (Cloud, Console, and PC)</li>
<li>Goat Simulator (PC)</li>
<li>Like a Dragon: Ishin! (Cloud, Console, and PC)</li>
<li>Like a Dragon: The Man Who Erased His Name (Cloud, Console, and PC)</li>
<li>Persona 5 Tactica (Cloud, Console, and PC)</li>
<li>Somerville (Cloud, Console, and PC)</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/10/41633013/sony-adds-new-death-note-game-to-november-ps-plus">Sony Adds New Death Note Game To November PS Plus</a></li>
</ul>
Image credits: Shutterstock.

Gaming

News

General

MSFT

Xbox Game Pass November: Metal Slug Tactics, Flight Simulator Lead New Releases

XMTR

Xometry shares are trading higher after the company reported better-than-expected Q3 financial results.

RBC Capital analyst Daniel Perlin maintains Fidelity National Info (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>) with a Outperform and raises the price target from $95 to $104.

Price Target

Analyst Ratings

RBC Capital Maintains Outperform on Fidelity National Info, Raises Price Target to $104

As Election Day 2024 unfolds, <a href="https://www.benzinga.com/topic/massachusetts">Massachusetts</a> and <a href="https://www.benzinga.com/topic/oregon">Oregon</a> are capturing national attention with pivotal ballot measures on psychedelics. Both states have the potential to reshape U.S. mental health treatment by advancing policies on substances like <a href="https://www.benzinga.com/topic/psilocybin">psilocybin</a> and <a href="https://www.benzinga.com/topic/mdma">MDMA</a>, part of the &#8220;psychedelic renaissance&#8221; in mental health care. These efforts signify growing momentum behind <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">psychedelic-assisted therapy</a> as a solution for PTSD, depression, and addiction, aiming to address urgent mental health needs.
<h3 class="wp-block-heading">Massachusetts' Question 4: Legalization And Regulation Of Psychedelics</h3>
Massachusetts voters face an important decision with Question 4, which would legalize and decriminalize psychedelics for therapeutic and personal use. If passed, it would allow licensed providers to administer substances like psilocybin and MDMA for therapy and decriminalize personal use and home cultivation of psilocybin.
This initiative marks Massachusetts&#8217; first state-level push for psychedelic reform, potentially setting a precedent for other states. However, the campaign has encountered internal disagreements, particularly around the measure's dual focus on therapeutic legalization and personal decriminalization, stirring debates on potential risks like unregulated recreational use.
<h3 class="wp-block-heading">Key Supporters And Opposition In Massachusetts</h3>
The campaign for Question 4 is backed by strong support from veterans groups and drug policy advocates. The Heroic Hearts Project, a veterans&#8217; service organization has been especially vocal. The group is promoting the measure as a critical alternative treatment for veterans suffering from PTSD and other mental health conditions. Massachusetts for Mental Health Options, the primary group <a href="https://www.benzinga.com/markets/cannabis/24/10/41320243/massachusetts-veterans-advocate-for-psilocybin-legalization-will-voters-support-them">backing the measure</a>, has received endorsements from numerous veteran advocates, who see psychedelics as a promising path to healing when traditional treatments fail.
<h3 class="wp-block-heading">Local Support</h3>
Eight<a href="https://www.benzinga.com/markets/cannabis/24/02/37158739/medford-massachusets-move-to-decriminalize-psychedelics-has-statewide-reform-implications"> Massachusetts cities</a> including Salem, Somerville and Cambridge have adopted policies deprioritizing the enforcement of laws against psychedelics. Cambridge and Somerville city councils endorsed the statewide ballot measure, signaling growing momentum for change at the local level.
Despite growing support, the measure has faced opposition. A majority of Massachusetts&#8217; Special Joint Committee on Ballot Initiatives recommended against it in May, citing concerns over its broad scope. Governor Maura Healey introduced a veterans-focused bill to study psilocybin's therapeutic potential but expressed caution about full-scale legalization. Critics say the measure's decriminalization and legalization could lead to unintended consequences, like increased recreational use or regulatory challenges. The No campaign, backed by groups like Smart Approaches to Marijuana, has raised public health concerns, urging voters to reject it.
Polls indicate that Massachusetts' electorate remains divided, with undecided voters likely to influence the final outcome. Voter turnout and public interpretation of the initiative's complexities could ultimately determine its success.
<h3 class="wp-block-heading">Oregon's Evolving Psychedelic Landscape</h3>
In Oregon, where voters approved psilocybin therapy with Measure 109 in 2020, the state is once again at the forefront of psychedelic reform. Following its landmark <a href="https://www.benzinga.com/markets/cannabis/20/11/18204455/oregon-becomes-first-us-state-to-decriminalize-drug-possession-begins-psilocybin-program">decriminalization of all drug possession</a> under Measure 110, Oregon is considering additional measures in 2024 to further expand access to psychedelic therapies, potentially addressing a wider array of mental health conditions and setting an example for other states.
These measures demonstrate Oregon's commitment to harm reduction and therapeutic options over punitive drug policies. For advocates nationwide, Oregon's ongoing initiatives offer a potential model for expanding regulated psychedelic therapy and decriminalization.
<h3 class="wp-block-heading">Federal Influence And Psychedelic Reform Movement</h3>
As <a href="https://www.benzinga.com/markets/cannabis/24/08/40447902/psychedelics-and-mental-health-fda-stalls-but-states-forge-ahead">state initiatives gain momentum</a>, federal policy on psychedelics remains uncertain. While the <a href="https://www.benzinga.com/topic/food-and-drug-administration">FDA</a> has approved limited research, broader legalization and therapeutic use are still unclear. However, bipartisan support for psychedelic research is growing. With votes on Massachusetts&#8217; Question 4 and Oregon&#8217;s initiatives, 2024 could be a pivotal year, particularly for MA, which may set a precedent for expanding access to transformative mental health therapies.
Cover image made with AI

Cannabis

Government

Psychedelics

Politics

Legal

2024 Election Spotlight: Massachusetts And Oregon Tackle Psychedelics Reform

Shares of MasTec Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>) continued their upward trajectory in early trading on Tuesday, after climbing last week on <a href="https://www.benzinga.com/news/24/11/41688665/amazon-posts-upbeat-results-joins-cardinal-health-waters-atlassian-charter-communications-mastec-and">the company's raised 2024 adjusted earnings guidance</a>.
Despite the recent rally, the stock has more runway. The Coral Gables, Florida-based company's Power Delivery, Clean Energy &amp; Infrastructure (CE&amp;I), and Communications segments are "turning the corner," according to Truist Securities.
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58ac4af1b85e930001e6383a/jamie-cook">Analyst Jamie Cook</a> upgraded the rating for MasTec from Hold to Buy, while raising the price target from $133 to $173.
The MasTec Thesis: The company's Power Delivery, CE&amp;I, and Communications segments are poised for revenue growth and margin expansion, Cook said in the upgrade note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
MasTec is "solidifying its positioning in utility transmission and distribution through the Henkels &amp; McCoy acquisition and in renewables through the IEA acquisition," the analyst stated. 
The company and rival Quanta Services Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>) are both "well positioned to lead the market and grow given competitive advantages which include scale, workforce, and balance sheet," he added.
"We expect strong top line growth and margin expansion in 2025 tied to secular growth in renewables, significant funding for communications infrastructure associated with BEAD funding and MTZ's recently expanded relationship with AT&amp;T (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>), and new major project wins including the $1.5 billion high-voltage transmission project MTZ announced last quarter," Cook wrote. After facing two years of margin pressure, MasTec seems poised for margin expansion in 2025 and "has line of sight to reaching double-digit EBITDA margins over the medium term," he further said.
Price Action: Shares of MasTechad risen by 3.22% to $136.87 at the time of publication on Tuesday.
Read More: <a href="https://www.benzinga.com/news/earnings/24/09/40859294/mastec-stock-rallies-31-in-the-past-6-months-is-mtz-a-buy-right-now">MasTec Stock Rallies 31% in the Past 6 Months: Is MTZ a Buy Right Now?</a>

Analyst Color

Long Ideas

Upgrades

Movers

Trading Ideas

Infrastructure Construction Company MasTec Is Poised For Double Digit Margin Expansion, Analyst Says

BOWL

Bowlero Corp shares are trading higher. JP Morgan maintained an Overweight rating on the stock.

Piper Sandler analyst Korinne Wolfmeyer reiterates Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) with a Neutral and raises the price target from $18 to $21.

Reiteration

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Piper Sandler Reiterates Neutral on Hims & Hers Health, Raises Price Target to $21

HCKT

Hackett Group shares are trading higher after the company reported better-than-expected Q3 financial results and issued Q4 adjusted EPS guidance above estimates. Also, Craig-Hallum raised its price target on the stock from $30 to $32.

In the current session, the stock is trading at $3.81, after a 3.81% increase. Over the past month, LexinFintech Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LX#NASDAQ">LX</a>) stock increased by 14.15%, and in the past year, by 80.20%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2024/1730824264_0.png" alt="Past Year Chart" />

<h3>LexinFintech Holdings P/E Compared to Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 24.2 in the Consumer Finance industry, LexinFintech Holdings Inc. has a lower P/E ratio of 5.3. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1730824264_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

A Look Into LexinFintech Holdings Inc's Price Over Earnings

Piper Sandler analyst Thomas Champion reiterates Vimeo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMEO#NASDAQ">VMEO</a>) with a Neutral and raises the price target from $5 to $7.

VMEO

Piper Sandler Reiterates Neutral on Vimeo, Raises Price Target to $7

NRG Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) has outperformed the market over the past 5 years by 5.24% on an annualized basis producing an average annual return of 18.49%. Currently, NRG Energy has a market capitalization of $17.75 billion. 
Buying $100 In NRG: If an investor had bought $100 of NRG stock 5 years ago, it would be worth $234.21 today based on a price of $86.00 for NRG at the time of writing.
<h3>NRG Energy's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730824226_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today

Datadog (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) has outperformed the market over the past 5 years by 16.86% on an annualized basis producing an average annual return of 30.12%. Currently, Datadog has a market capitalization of $42.19 billion. 
Buying $1000 In DDOG: If an investor had bought $1000 of DDOG stock 5 years ago, it would be worth $3,814.23 today based on a price of $125.14 for DDOG at the time of writing.
<h3>Datadog's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730824221_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DDOG

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,800 Today

Clearwater Paper shares are trading higher. RBC Capital reiterated an Outperform rating on the stock.

ICHR

Ichor Holdings shares are trading higher after the company reported better-than-expected Q3 financial results and issued Q4 revenue guidance above estimates. Also. B. Riley Securities raised its price target on the stock from $36 to $38.

INGR

Ingredion shares are trading higher after the company reported better-than-expected Q3 adjusted EPS results and raised its FY24 adjusted EPS guidance above estimates.

Piper Sandler analyst Adam Maeder reiterates Inspire Medical Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSP#NYSE">INSP</a>) with a Overweight and raises the price target from $255 to $260.

INSP

Piper Sandler Reiterates Overweight on Inspire Medical Systems, Raises Price Target to $260

RBC Capital analyst Conor McNamara maintains Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a Sector Perform and raises the price target from $86 to $89.

HOLX

RBC Capital Maintains Sector Perform on Hologic, Raises Price Target to $89

AOSL

Alpha & Omega shares are trading lower after the company reported worse-than-expected Q1 adjusted EPS results. B. Riley Securities lowered its price target on the stock from $50 to $47.

Here is how many Chinese ADRs are performing from the past week

DBS analyst Sachin Mittal maintained a Buy rating on Trip.com Group Ltd. (9961 – Research Report) today and set a price target of HK$620.00. The co...

Trip.com Group Ltd. (9961) Gets a Buy from DBS

6 Fundamentally Strong Beaten-Up Stocks

China-related stocks give back gain due to lack of details on stimulus measures

China-related stocks give back gains due to lack of details on stimulus measures

U.S.-listed Chinese stocks gain ahead of China's potential $283B fiscal stimulus package

Booking Holdings: There And Back Again

Top Consumer Discretionary stocks don't include the surging Tesla, as per SA quant grades

Harding Loevner Emerging Markets Equity Q3 2024 Report

Bernstein analyst Boris Van initiated coverage of Trip.com (TCOM) with an Outperform rating and $85 price target The company is a leader in its sec...

Trip.com initiated with an Outperform at Bernstein

AAGIY

AAIGF

ABNB

AMPH

ASHR

ATHM

BABA

BDGSF

BIDU

BILI

BKNG

BZUN

CAAP

CHIQ

CLCGY

CNYA

CQQQ

CUKPF

DADA

EXPE

FIGIF

FLCH

FLXS

FYGGY

GOTU

HNHAF

HNHPF

HXSCF

JDCMF

KWEB

LUKOY

MCHI

MOMO

NTES

PTON

SSNLF

STRL

STRT

TCOM

TOUR

TOYOF

TRPCF

TSLA

TTNDF

TTNDY

TWLO

VIPS

VIRC

VSCO

WEGZY

WMMVF

WMMVY

XPEV

YANG

YINN

YUMC

Press Releases

Trip.com Group Limited to Report First Quarter of 2024 Financial Results on May 20, 2024 U.S. Time

Earnings

Trip.com Group Limited Reports Unaudited First Quarter of 2024 Financial Results

Trip.com Group to Hold Annual General Meeting on June 18, 2024

Trip.com Group Limited Announces Proposed Offering of US$1.3 Billion Cash-par Settled Convertible Senior Notes

Offerings

Trip.com Group Limited Announces Pricing of Offering of US$1.3 Billion Cash-par Settled Convertible Senior Notes

Trip.com Group Limited Announces Completion of Offering of US$1.5 Billion Cash-par Settled Convertible Senior Notes

Trip.com Group Limited to Report Second Quarter and First Half of 2024 Financial Results on August 26, 2024 U.S. Time

Trip.com Group Limited Reports Unaudited Second Quarter and First Half of 2024 Financial Results

Entertainment

Trip.com Group Highlights Golden Week 2024 Travel Shifts: Chinese Tourists Explore Beyond Capitals and Lesser-Known Options

Trip.com Group Limited to Report Third Quarter of 2024 Financial Results on November 18, 2024 U.S. Time

Airbnb

Atour Lifestyle Holdings Limited - American Depositary Shares

Atour Lifestyle Holdings

Booking Holdings

Choice Hotels International, Inc. Common Stock

Choice Hotels Intl

Despegar.com

Expedia Group

Global Business Travel Group, Inc. Class A Common Stock

Global Business Travel

GreenTree Hospitality Group Ltd. American depositary shares, each representing one Class A ordinary share

GreenTree Hospitality Gr

Hyatt Hotels Corporation Class A Common Stock

Hyatt Hotels

Hilton Grand Vacations

Hilton Worldwide Holdings Inc. Common Stock

Hilton Worldwide Holdings

H World Group Limited - American Depositary Shares

H World Group

Intercontinental Hotels Group American Depositary Shares (Each representing one Ordinary Share)

Comments

Trip.com Group

空売り

Trip.com Group (NASDAQ:TCOM) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル